2021

1. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

   Reumatologia Clinica, Vol. 17, Núm. 10, pp. 559-561

2. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

   Journal of Clinical Medicine, Vol. 10, Núm. 9